300639 Stock Overview
Engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 1/6 |
Financial Health | 4/6 |
Dividends | 2/6 |
Guangdong Hybribio Biotech Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥6.68 |
52 Week High | CN¥10.08 |
52 Week Low | CN¥4.32 |
Beta | 0.39 |
11 Month Change | 46.17% |
3 Month Change | 11.15% |
1 Year Change | -30.34% |
33 Year Change | -52.68% |
5 Year Change | 9.54% |
Change since IPO | 70.47% |
Recent News & Updates
Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) 77% Share Price Surge Not Quite Adding Up
Aug 19Guangdong Hybribio BiotechLtd (SZSE:300639) Is Reducing Its Dividend To CN¥0.065
May 22Shareholder Returns
300639 | CN Biotechs | CN Market | |
---|---|---|---|
7D | 17.4% | 0.03% | -0.3% |
1Y | -30.3% | -20.4% | -18.1% |
Return vs Industry: 300639 underperformed the CN Biotechs industry which returned -20.4% over the past year.
Return vs Market: 300639 underperformed the CN Market which returned -18.1% over the past year.
Price Volatility
300639 volatility | |
---|---|
300639 Average Weekly Movement | 9.8% |
Biotechs Industry Average Movement | 5.7% |
Market Average Movement | 5.6% |
10% most volatile stocks in CN Market | 8.9% |
10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 300639's share price has been volatile over the past 3 months.
Volatility Over Time: 300639's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 2,669 | Jianyu Wang | www.hybribio.cn |
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal.
Guangdong Hybribio Biotech Co.,Ltd. Fundamentals Summary
300639 fundamental statistics | |
---|---|
Market cap | CN¥5.20b |
Earnings (TTM) | CN¥60.76m |
Revenue (TTM) | CN¥985.44m |
70.6x
P/E Ratio4.4x
P/S RatioIs 300639 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300639 income statement (TTM) | |
---|---|
Revenue | CN¥985.44m |
Cost of Revenue | CN¥417.24m |
Gross Profit | CN¥568.21m |
Other Expenses | CN¥507.44m |
Earnings | CN¥60.76m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
Earnings per share (EPS) | 0.095 |
Gross Margin | 57.66% |
Net Profit Margin | 6.17% |
Debt/Equity Ratio | 0.6% |
How did 300639 perform over the long term?
See historical performance and comparison